Prostatic Artery Embolization (PAE) Using Polyethylene Glycol Microspheres: Safety and Efficacy in 81 Patients.
Lower urinary tract symptoms
Prostatic artery embolization
Prostatic hyperplasia
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
27
11
2021
accepted:
26
04
2022
pubmed:
3
6
2022
medline:
14
9
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
To evaluate the safety and efficacy of prostatic artery embolization (PAE) using polyethylene glycol microspheres (PEGM) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). This multicentric prospective study enrolled 81 patients who underwent PAE with 400 ± 75 µm PEGM (HydroPearl®, Terumo, Japan). Results from baseline and 1-, 3-, 6-, and 12-month follow-ups were assessed for subjective outcomes including International Prostate Symptoms Score (IPSS), Quality of life (QoL), and International Index of Erectile Function, and objective outcomes such as peak urinary flow (Qmax) and post-void residual volume (PVR). The visual analogue scale, satisfaction questionnaire, prostatic volume, and prostatic specific antigen levels were also evaluated. Complications were documented using the modified Clavien-Dindo classification. Technical success was obtained in all patients. Clinical success was achieved in 78.5% of patients. Before PAE, 54.3% of patients had an indwelling catheter which was removed in 75% of them after procedure. A statistically significant decrease was observed in IPSS and QoL from baseline to 12 months (20.14 vs 5.89; 4.8 vs 0.63, P < .01), respectively. Objective outcomes also showed a statistically significant improvement in Qmax (+ 114.9%; P < .01), achieving a maximum urinary flow of 14.2 mL/sec, and PVR (decrease 58%; P < .05) at 12 months. Minor complications (Clavien-Dindo grades I-II) occurred in 13.6% of patients, without major complications observed. PAE with PEGM is safe and effective treatment in patients with symptomatic BPH, with a significant improvement in both subjective and objective outcomes.
Identifiants
pubmed: 35655035
doi: 10.1007/s00270-022-03165-4
pii: 10.1007/s00270-022-03165-4
pmc: PMC9458568
doi:
Substances chimiques
Polyethylene Glycols
3WJQ0SDW1A
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1339-1348Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Uflacker A, Haskal ZJ, Bilhim T, Patrie J, Huber T, Pisco JM. Meta-analysis of prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol. 2016;27(11):1686-1697.e8.
doi: 10.1016/j.jvir.2016.08.004
Knight GM, Talwar A, Salem R, Mouli S. Systematic review and meta-analysis comparing prostatic artery embolization to gold-standard transurethral resection of the prostate for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2021;44(2):183–93.
doi: 10.1007/s00270-020-02657-5
Xiang P, Guan D, Du Z, Hao Y, Yan W, Wang Y, et al. Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol. 2021;31(7):4929–46.
doi: 10.1007/s00330-020-07663-2
Bilhim T, Pisco J, Pereira JA, Costa NV, Fernandes L, Pinheiro LC, et al. Predictors of clinical outcome after prostate artery embolization with spherical and nonspherical polyvinyl alcohol particles in patients with benign prostatic hyperplasia. Radiology. 2016;281(1):289–300.
doi: 10.1148/radiol.2016152292
Bilhim T, Pisco J, Campos Pinheiro L, Rio Tinto H, Fernandes L, Pereira JA, et al. Does polyvinyl alcohol particle size change the outcome of prostatic arterial embolization for benign prostatic hyperplasia? Results from a single-center randomized prospective study. J Vasc Interv Radiol. 2013;24(11):1595–602.
doi: 10.1016/j.jvir.2013.06.003
Wang MQ, Zhang JL, Xin HN, Yuan K, Yan J, Wang Y, et al. Comparison of clinical outcomes of prostatic artery embolization with 50-μm Plus 100-μm polyvinyl alcohol (PVA) particles versus 100-μm PVA particles alone: a prospective randomized trial. J Vasc Interv Radiol. 2018;29(12):1694–702.
doi: 10.1016/j.jvir.2018.06.019
Torres D, Costa NV, Pisco J, Pinheiro LC, Oliveira AG, Bilhim T. Prostatic artery embolization for benign prostatic hyperplasia: prospective randomized trial of 100–300 μm versus 300–500 μm versus 100- to 300-μm + 300- to 500-μm embospheres. J Vasc Interv Radiol. 2019;30(5):638–44.
doi: 10.1016/j.jvir.2019.02.014
Bilhim T. Endovascular resection of the prostate: how much is enough for prostate artery embolization? J Vasc Interv Radiol. 2019;30(2):225–7.
doi: 10.1016/j.jvir.2018.10.009
Isaacson AJ, Raynor MC, Yu H, Burke CT. Prostatic artery embolization using embosphere microspheres for prostates measuring 80–150 cm(3): early results from a US trial. J Vasc Interv Radiol. 2016;27(5):709–14.
doi: 10.1016/j.jvir.2016.01.146
Carnevale FC, Moreira AM, Antunes AA. The “PErFecTED technique”: proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014;37(6):1602–5.
doi: 10.1007/s00270-014-0908-z
Bilhim T. Prostatic artery embolization for benign prostatic hyperplasia: a 10-year update. Endovasc Today. 2020;19:40–4.
Patetta MA, Isaacson AJ, Stewart JK. Initial experience with hydropearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids. CVIR Endovasc. 2021;4(1):1–7.
doi: 10.1186/s42155-021-00223-9
Lucas Cava V, Sánchez Margallo FM, Báez Díaz C, Dávila Gómez L, Lima Rodríguez JR, Sun F. Prostatic artery embolization with polyethylene glycol microspheres: evaluation in a canine spontaneous benign prostatic hyperplasia model. CVIR Endovasc. 2020;3(1):1–8.
doi: 10.1186/s42155-020-00130-5
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373–4.
Dixon JRJ. The international conference harmonization good clinical practice guideline. Qual Assur. 1998;6(2):65–74.
doi: 10.1080/105294199277860
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800–4.
doi: 10.1097/EDE.0b013e3181577654
Cornelis FH, Bilhim T, Hacking N, Sapoval M, Tapping CR, Carnevale FC. CIRSE standards of practice on prostatic artery embolisation. Cardiovasc Intervent Radiol. 2020;43(2):176–85.
doi: 10.1007/s00270-019-02379-3
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
Insausti I, Sáez de OcárizGalbete AA, Capdevila F, Solchaga S, Giral P, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2020;31(6):882–90.
doi: 10.1016/j.jvir.2019.12.810
Abt D, Hechelhammer L, Müllhaupt G, Markart S, Güsewell S, Kessler TM, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Randomised, open label, non-inferiority trial. BMJ. 2018. https://doi.org/10.1136/bmj.k2338 .
doi: 10.1136/bmj.k2338
Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, Morgia G, et al. Prostatic artery embolization for prostate volume greater than 80 cm3: results from a single-center prospective study. Urology. 2014;84(2):400–4.
doi: 10.1016/j.urology.2014.04.028
Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM, Papadouris D, et al. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014;25(1):47–52.
doi: 10.1016/j.jvir.2013.09.010
Gonçalves OM, Carnevale FC, Moreira AM, Antunes AA, Rodrigues VC, Srougi M. Comparative study using 100–300 versus 300–500 μm microspheres for symptomatic patients due to enlarged-BPH prostates. Cardiovasc Intervent Radiol. 2016;39(10):1372–8.
doi: 10.1007/s00270-016-1443-x
Ayyagari R, Powell T, Staib L, Chapiro J, Raja A, Bhatia S, et al. Prostatic artery embolization using 100–300-μm trisacryl gelatin microspheres to treat lower urinary tract symptoms attributable to benign prostatic hyperplasia: a single-center outcomes analysis with medium-term follow-up. J Vasc Interv Radiol. 2020;31(1):99–107.
doi: 10.1016/j.jvir.2019.08.005
Pisco JM, Rio Tinto H, Campos Pinheiro L, Bilhim T, Duarte M, Fernandes L, et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol. 2013;23(9):2561–72.
doi: 10.1007/s00330-012-2714-9
Sun F, Crisóstomo V, Báez-Díaz C, Sánchez FM. Prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH): Part 2, insights into the technical rationale. Cardiovasc Intervent Radiol. 2016;39(2):161–9.
doi: 10.1007/s00270-015-1238-5
Costa NV, Pisco JM, Bilhim T, Pinheiro L, Fernandes L, Pereira JA, et al. The safety and efficacy of prostatic arteries embolization with polyzene-coated microspheres (Embozene) for benign prostatic hyperplasia—preliminary results. J Vasc Interv Radiol. 2015;26(2):S155.
doi: 10.1016/j.jvir.2014.12.418
Ayyagari R, Powell T, Staib L, Chapiro J, Perez-Lozada J-C, Bhatia S, et al. Prostatic artery embolization in nonindex benign prostatic hyperplasia patients: single-center outcomes for urinary retention and gross prostatic hematuria. Urology. 2020;136:212–7.
doi: 10.1016/j.urology.2019.11.003
Carnevale FC, Da Motta-Leal-Filho JM, Antunes AA, Baroni RH, Marcelino ASZ, Cerri LMO, et al. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2013;24(4):535–42.
doi: 10.1016/j.jvir.2012.12.019
Rampoldi A, Barbosa F, Secco S, Migliorisi C, Galfano A, Prestini G, et al. Prostatic artery embolization as an alternative to indwelling bladder catheterization to manage benign prostatic hyperplasia in poor surgical candidates. Cardiovasc Intervent Radiol. 2017;40(4):530–6.
doi: 10.1007/s00270-017-1582-8
Bhatia S, Sinha VK, Kava BR, Gomez C, Harward S, Punnen S, et al. Efficacy of prostatic artery embolization for catheter-dependent patients with large prostate sizes and high comorbidity scores. J Vasc Interv Radiol. 2018;29(1):78-84.e1.
doi: 10.1016/j.jvir.2017.08.022
Kenny AG, Pellerin O, Amouyal G, Desgranchamps F, Méria P, De Gouvello A, et al. Prostate artery embolization in patients with acute urinary retention. Am J Med. 2019;132(11):e786–90.
doi: 10.1016/j.amjmed.2019.04.037
Antunes AA, Carnevale FC, Da Motta Leal Filho JM, Yoshinaga EM, Cerri LMO, Baroni RH, et al. Clinical, laboratorial, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. a prospective single-center pilot study. Cardiovasc Intervent Radiol. 2013;36(4):978–86.
doi: 10.1007/s00270-013-0611-5
Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective. Urodyn-Controlled Anal Cardiovasc Intervent Radiol. 2016;39(1):44–52.
doi: 10.1007/s00270-015-1202-4
Hacking N, Vigneswaran G, Maclean D, Modi S, Dyer J, Harris M, et al. Technical and imaging outcomes from the UK registry of prostate artery embolization (UK-ROPE) study: focusing on predictors of clinical success. Cardiovasc Intervent Radiol. 2019;42(5):666–76.
doi: 10.1007/s00270-018-02156-8
Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115–22.
doi: 10.1016/j.jvir.2016.04.001
Pisco JM, Bilhim T, Costa NV, Torres D, Pisco J, Pinheiro LC, et al. Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol. 2020;77(3):354–62.
doi: 10.1016/j.eururo.2019.11.010
Marzano L, Thiounn N, Pereira H, Pellerin O, Dariane C, Del Giudice C, et al. Prostatic artery embolization allows to maintain full sexual activity in patients suffering from bothersome lower urinary tracts symptoms related to benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2020;43(8):1202–7.
doi: 10.1007/s00270-020-02520-7